Department of Psychiatry and Behavioral Sciences, and Center for Health and Community, University of California, San Francisco, San Francisco, California (E.G.D., E.S.E., A.A.P.).
Department of Psychiatry and Behavioral Sciences, and Osher Center for Integrative Health, University of California, San Francisco, San Francisco, California (A.E.M.).
Ann Intern Med. 2024 Jul;177(7):892-900. doi: 10.7326/M23-2956. Epub 2024 Jun 11.
Concern about side effects is a common reason for SARS-CoV-2 vaccine hesitancy.
To determine whether short-term side effects of SARS-CoV-2 messenger RNA (mRNA) vaccination are associated with subsequent neutralizing antibody (nAB) response.
Prospective cohort study.
San Francisco Bay Area.
Adults who had not been vaccinated against or exposed to SARS-CoV-2, who then received 2 doses of either BNT162b2 or mRNA-1273.
Serum nAB titer at 1 month and 6 months after the second vaccine dose. Daily symptom surveys and objective biometric measurements at each dose.
363 participants were included in symptom-related analyses (65.6% female; mean age, 52.4 years [SD, 11.9]), and 147 were included in biometric-related analyses (66.0% female; mean age, 58.8 years [SD, 5.3]). Chills, tiredness, feeling unwell, and headache after the second dose were each associated with 1.4 to 1.6 fold higher nAB at 1 and 6 months after vaccination. Symptom count and vaccination-induced change in skin temperature and heart rate were all positively associated with nAB across both follow-up time points. Each 1 °C increase in skin temperature after dose 2 was associated with 1.8 fold higher nAB 1 month later and 3.1 fold higher nAB 6 months later.
The study was conducted in 2021 in people receiving the primary vaccine series, making generalizability to people with prior SARS-CoV-2 vaccination or exposure unclear. Whether the observed associations would also apply for neutralizing activity against non-ancestral SARS-CoV-2 strains is also unknown.
Convergent self-report and objective biometric findings indicate that short-term systemic side effects of SARS-CoV-2 mRNA vaccination are associated with greater long-lasting nAB responses. This may be relevant in addressing negative attitudes toward vaccine side effects, which are a barrier to vaccine uptake.
National Institute on Aging.
对副作用的担忧是新冠病毒疫苗犹豫的常见原因。
确定新冠病毒信使 RNA（mRNA）疫苗的短期副作用是否与随后的中和抗体（nAB）反应相关。
前瞻性队列研究。
旧金山湾区。
未接种或未接触过 SARS-CoV-2 的成年人，随后接种了 BNT162b2 或 mRNA-1273 的两剂疫苗。
第二剂疫苗后 1 个月和 6 个月的血清 nAB 滴度。每次剂量时的每日症状调查和客观生物计量测量。
363 名参与者纳入了与症状相关的分析（65.6%为女性；平均年龄 52.4 岁[SD，11.9]），147 名参与者纳入了与生物计量相关的分析（66.0%为女性；平均年龄 58.8 岁[SD，5.3]）。第二剂疫苗后发冷、疲倦、不适和头痛与接种后 1 个月和 6 个月的 nAB 增加 1.4 至 1.6 倍有关。症状计数以及接种后皮肤温度和心率的变化与两次随访时间点的 nAB 均呈正相关。剂量 2 后皮肤温度每升高 1°C，与 1 个月后 nAB 增加 1.8 倍和 6 个月后 nAB 增加 3.1 倍有关。
该研究于 2021 年在接受初级疫苗系列的人群中进行，对于先前接种过 SARS-CoV-2 疫苗或暴露的人群的普遍性尚不清楚。观察到的关联是否也适用于针对非原始 SARS-CoV-2 株的中和活性也不清楚。
自我报告和客观生物计量学的综合发现表明，新冠病毒 mRNA 疫苗的短期全身副作用与更持久的 nAB 反应相关。这可能与解决对疫苗副作用的负面态度有关，这是疫苗接种率的一个障碍。
美国国立卫生研究院老龄化研究所。
